West Pharmaceutical Services, Inc.
WST
$230.11
$6.382.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.92% | -1.71% | 0.38% | 1.56% | 2.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.92% | -1.71% | 0.38% | 1.56% | 2.18% |
| Cost of Revenue | 4.12% | 3.36% | 4.40% | 4.49% | 3.95% |
| Gross Profit | -11.64% | -9.96% | -6.14% | -3.03% | -0.55% |
| SG&A Expenses | -5.42% | 14.44% | 7.28% | 11.36% | 12.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -30.77% | 850.00% | -50.00% | 9.09% | 161.90% |
| Total Operating Expenses | 2.50% | 5.00% | 4.97% | 5.76% | 5.68% |
| Operating Income | -15.94% | -21.23% | -13.75% | -10.54% | -7.54% |
| Income Before Tax | -16.14% | -10.55% | 0.11% | 2.18% | 2.16% |
| Income Tax Expenses | -12.10% | -9.85% | -5.11% | -1.71% | 6.63% |
| Earnings from Continuing Operations | -16.97% | -10.69% | 1.20% | 3.01% | 1.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.97% | -10.69% | 1.20% | 3.01% | 1.28% |
| EBIT | -15.94% | -21.23% | -13.75% | -10.54% | -7.54% |
| EBITDA | -11.20% | -15.99% | -9.30% | -6.88% | -4.62% |
| EPS Basic | -15.47% | -9.46% | 2.02% | 3.48% | 1.42% |
| Normalized Basic EPS | -14.66% | -20.14% | -12.47% | -9.22% | -6.53% |
| EPS Diluted | -14.97% | -9.22% | 2.27% | 3.93% | 1.89% |
| Normalized Diluted EPS | -14.24% | -19.75% | -12.09% | -8.84% | -6.13% |
| Average Basic Shares Outstanding | -1.75% | -1.38% | -0.91% | -0.50% | -0.13% |
| Average Diluted Shares Outstanding | -2.22% | -1.85% | -1.36% | -0.92% | -0.56% |
| Dividend Per Share | 5.19% | 5.26% | 5.33% | 5.41% | 5.48% |
| Payout Ratio | 0.25% | 0.17% | 0.03% | 0.02% | 0.04% |
